|
| Status |
Public on Oct 16, 2018 |
| Title |
299R-4 |
| Sample type |
RNA |
| |
|
| Source name |
HT1080
|
| Organism |
Homo sapiens |
| Characteristics |
genotype/variation: resistant to PTC299
|
| Growth protocol |
PTC299-resistant and parent HT1080 cells were seeded in 6-well plates (5 x 105 cells/well) and incubated overnight.
|
| Extracted molecule |
total RNA |
| Extraction protocol |
Total RNA was purified with RNeasy Mini Kit (Qiagen) according to the manufacturer’s instructions. cRNA was prepared according to the standard Affymetrix protocol.
|
| Label |
biotin
|
| Label protocol |
standard Affymetrix protocol
|
| |
|
| Hybridization protocol |
cRNA was hybridized at 45oC for 16 h on a GeneChip Human Genome U133 plus 2.0 Array.
|
| Scan protocol |
GeneChips were analyzed using the Affymetrix scanner.
|
| Data processing |
Data analysis was performed using Transcriptome Analysis Console (TAC) Software (Thermo Fisher Scientific). The MAS5 normalization method was used. ANOVA was used for statistical evaluation.
|
| |
|
| Submission date |
Oct 15, 2018 |
| Last update date |
Oct 16, 2018 |
| Contact name |
Wencheng Li |
| Organization name |
PTC Therapeutics
|
| Street address |
100 Corporate Count
|
| City |
South Plainfield |
| State/province |
NJ - New Jersey |
| ZIP/Postal code |
07080 |
| Country |
USA |
| |
|
| Platform ID |
GPL570 |
| Series (1) |
| GSE121266 |
Targeting of Hematologic Malignancies with PTC299, A Novel Potent Inhibitor of Dihydroorotate Dehydrogenase with Favorable Pharmaceutical Properties |
|
